4
MARKET OVERVIEW
Outlines emerging trends, technology impact, and regulatory signals affecting growth trajectory and stakeholder decisions.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Explains the evolving landscape through demand-side drivers, supply-side constraints, and opportunity hotspots.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITION RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.1
GDP TRENDS AND FORECAST
5.2.2
TRENDS IN EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET
5.2.3
TRENDS IN EUROPE HEALTHCARE/PHARMA INDUSTRY
5.4.1
EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS
5.5.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT (2022–2024)
5.5.2
AVERAGE SELLING PRICE TREND, BY COUNTRY (2022–2024)
5.7
KEY CONFERENCES AND EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.9.1
VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE
5.10
IMPACT OF 2025 US TARIFF – EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES/REGIONS
5.10.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1.1
SOLID-PHASE SYNTHESIS
6.1.2
LIQUID-PHASE SYNTHESIS
6.1.3
ENZYMATIC OLIGO SYNTHESIS
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
POLYMERASE CHAIN REACTION (PCR)
6.2.2
NEXT-GENERATION SEQUENCING (NGS)
6.2.3
MICROARRAY ANALYSIS
6.3
ADJACENT TECHNOLOGIES
6.3.2
LIPID NANOPARTICLES
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.8
IMPACT OF AI/GEN AI ON EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET
6.8.1
TOP USE CASES AND MARKET POTENTIAL
6.8.2
CASE STUDIES OF AI IMPLEMENTATION IN EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET
6.8.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.8.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
9.2
OLIGONUCLEOTIDE-BASED DRUGS
9.2.1
OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
9.2.1.1
ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
9.2.1.2
SIRNA OLIGONUCLEOTIDE-BASED DRUGS
9.2.1.3
OTHER OLIGONUCLEOTIDE-BASED DRUGS
9.3
SYNTHESIZED OLIGONUCLEOTIDES
9.3.1
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
9.3.1.3
DNA OLIGONUCLEOTIDES
9.3.1.4
RNA OLIGONUCLEOTIDES
9.3.1.5
OTHER SYNTHESIZED OLIGONUCLEOTIDES
9.3.2
SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
9.3.2.1
CUSTOM OLIGONUCLEOTIDES
9.3.2.2
PREDESIGNED OLIGONUCLEOTIDES
9.4
REAGENTS & CONSUMABLES
10
EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
10.2
THERAPEUTIC APPLICATIONS
10.2.1
THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
10.2.1.1
NEUROLOGICAL DISORDERS
10.3
RESEARCH APPLICATIONS
10.3.3
OTHER RESEARCH APPLICATIONS
10.4
DIAGNOSTIC APPLICATIONS
11
EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)
11.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.4
DIAGNOSTIC LABORATORIES
11.5
CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
11.6
ACADEMIC RESEARCH INSTITUTES
12
EUROPE OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2023–2030 (USD MILLION)
ASSESSMENT OF GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY EUROPEAN COUNTRIES
12.2.7
MACROECONOMIC OUTLOOK OF EUROPE
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
13.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3
REVENUE ANALYSIS, 2022–2024
13.4
MARKET SHARE ANALYSIS,
13.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
13.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
13.5.5.1
COMPANY FOOTPRINT
13.5.5.2
REGION FOOTPRINT
13.5.5.3
PRODUCT FOOTPRINT
13.5.5.4
APPLICATION FOOTPRINT
13.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
13.6.1
PROGRESSIVE COMPANIES
13.6.2
RESPONSIVE COMPANIES
13.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
13.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
13.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
13.8
VALUATION AND FINANCIAL METRICS
13.9
COMPETITIVE SCENARIO
13.9.3
OTHER DEVELOPMENTS
14.1.1
THERMO FISHER SCIENTIFIC, INC.
14.1.2
DANAHER CORPORATION
14.1.5
EUROFINS SCIENTIFIC
14.1.10
JAZZ PHARMACEUTICALS PLC
NOTE: THE DETAILS ON BUSINESS OVERVIEW, FINANCIAL INFORMATION, PRODUCT PORTFOLIO, RECENT DEVELOPMENTS, MARKETSANDMARKETS VIEW WILL BE PROVIDED FOR ~25 COMPANIES. THESE DETAILS MIGHT NOT BE CAPTURED IN THE CASE OF UNLISTED COMPANIES. THE PROVIDED LIST OF P
15.1.1.1
KEY SOURCES OF SECONDARY DATA
15.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
15.1.2.1
BREAKDOWN OF PRIMARIES
15.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
15.2
MARKET SIZE ESTIMATION
15.2.1
EUROPE OLIGONUCLEOTIDE SYNTHESIS SIZE ESTIMATION
15.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
15.2.1.2
MNM REPOSITORY ANALYSIS
15.2.1.3
SECONDARY ANALYSIS
15.2.1.4
PRIMARY RESEARCH
15.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
15.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
15.3
MARKET GROWTH RATE PROJECTIONS
15.6
RESEARCH ASSUMPTIONS
15.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
16.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Europe Oligonucleotide Synthesis Market